| Literature DB >> 35155679 |
Zahra Nasehi1, Nejat Kheiripour1, Maryam Akhavan Taheri2, Abolfazl Ardjmand3, Faezeh Jozi4, Esmat Aghadavod1,4, Amir Hossein Doustimotlagh5, Mohammad Esmaeil Shahaboddin1,4.
Abstract
This study is aimed at evaluating the effects of Securigera securidaca (SS) seed extract on cholestatic liver injury induced by bile duct ligation (BDL) in rats. Total polyphenols and flavonoids in SS seed extract were determined using a colorimetric assay, and their components were quantified using HPLC. Rats in four groups underwent BDL at the common bile duct and were treated for 21 days with either oral distilled water as vehicle, vitamin C, 100 mg/kg SS seed extract, or 200 mg/kg SS seed extract. Rats in the fifth group underwent abdominal incision without BDL and were treated with distilled water, and rats in the sixth group were healthy and received nothing. Finally, rats were sacrificed, blood samples were analyzed through biochemical methods, liver tissues were histologically assessed, and the expression of the TGFβ-1, iNOS, caspase-3, and α-SMA genes in the liver was assessed through real-time PCR. BDL significantly increased, and SS seed extract significantly decreased the serum levels of bilirubin and liver function enzymes. Moreover, SS seed extract suppressed the expression of the TGFβ-1, iNOS, caspase-3, and α-SMA genes, reduced the levels of nitric oxide, malondialdehyde, and protein carbonyl, and increased the levels of glutathione, total antioxidant capacity, and SOD and catalase enzyme activity in the serum and liver. Extract at a dose of 100 mg/kg had significant positive effects on liver morphology and parenchyma structure in a dose-dependent manner.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35155679 PMCID: PMC8837422 DOI: 10.1155/2022/6989963
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Chromatogram of Securigera securidaca extract. Chromatogram of three standard mixtures of phenolic compounds was depicted. The standard phenolic compounds include (1) apigenin 7-glycoside, (2) luteolin, and (3) isorhamnetin. Three phenolic compounds identified in SS hydroalcoholic extract were labeled.
Group comparisons respecting the mean scores of liver injury biochemical factors and oxidative stress markers.
| Markers | Groups | |||||
|---|---|---|---|---|---|---|
| Healthy mean ± SD | Sham mean ± SD | BDL-control mean ± SD | BDL+VitC mean ± SD | BDL+SS100 mean ± SD | BDL+SS200 mean ± SD | |
|
| ||||||
| AST (IU/L) | 182.8 ± 9.26∗^ | 203.8 ± 15.87∗^ | 268.4 ± 11.01# | 249 ± 13.67# | 214 ± 6.52∗^ | 237.8 ± 8.9#∗ |
| LT (IU/L) | 81.6 ± 7.47∗^ | 94.2 ± 7.01∗^ | 150.2 ± 8.12#^ | 108.6 ± 7.83#∗ | 125.4 ± 7.02#∗^ | 134.2 ± 6.38#∗^ |
| LP (IU/L) | 544.6 ± 36.91∗^ | 715.8 ± 69.32∗^ | 1316.2 ± 215.11#^ | 1076.4 ± 117.43#∗ | 804.6 ± 181.46∗^ | 970 ± 46.83#∗ |
| LDH (IU/L) | 2327.8 ± 141.81∗∧ | 2621.2 ± 88.72∗∧ | 4084.8 ± 129.45# | 3784.2 ± 108.36# | 3148 ± 150.65#∗∧ | 3466 ± 207.72#∗∧ |
| Total bilirubin (mg/dL) | 0.3 ± 0∗∧ | 0.4 ± 0∗∧ | 8.08 ± 1.15# | 6.44 ± 2.37# | 3.14 ± 0.6#∗∧ | 4.08 ± 0.37#∗∧ |
| Direct bilirubin (mg/dL) | 0.1 ± 0∗∧ | 0.1 ± 0∗∧ | 6.1 ± 1.14# | 5.26 ± 0.36# | 1.58 ± 0.65#∗∧ | 2.17 ± 0.81#∗∧ |
|
| ||||||
| Liver NO ( | 0.113 ± 0.02#∗∧ | 0.17 ± 0.01∗∧ | 0.4 ± 0.02#∧ | 0.29 ± 0.01#∗ | 0.228 ± 0.03#∗∧ | 0.29 ± 0.01#∗ |
| Liver MDA ( | 2.8 ± 0.56∗∧ | 3.23 ± 0.45∗∧ | 10.19 ± 0.42# | 10.72 ± 0.7# | 6.03 ± 0.33#∗∧ | 10.16 ± 0.39# |
| Liver protein carbonyl ( | 926.64 ± 23.81#∗∧ | 1023.61 ± 27.75∗∧ | 1224.45 ± 35.03# | 1201.8 ± 34.86# | 1174.95 ± 32.81#∧ | 1037.98 ± 23.46∗∧ |
| Liver TAC ( | 1.226 ± 0.05∗∧ | 1.166 ± 0.05∗∧ | 0.728 ± 0.03# | 0.74 ± 0.04# | 0.748 ± 0.03# | 0.846 ± 0.04#∗∧ |
| Liver GSH (mmol/mg protein) | 0.073 ± 0.001#∗∧ | 0.064 ± 0.011∗∧ | 0.024 ± 0.002# | 0.028 ± 0.001# | 0.048 ± 0.003#∗∧ | 0.042 ± 0.002#∗∧ |
| Liver SOD (U/mg protein) | 6.26 ± 0.67∗∧ | 6.18 ± 0.25∗∧ | 4.73 ± 0.25# | 5.09 ± 0.28# | 5.8 ± 0.36∗∧ | 5.41 ± 0.28#∗ |
| Liver catalase (U/mg protein) | 33.92 ± 2.22#∗∧ | 30.76 ± 1.23∗∧ | 22.1 ± 1.54# | 24.33 ± 0.58# | 27.95 ± 1.16∗∧ | 26.32 ± 1.02#∗ |
| Serum NO ( | 0.084 ± 0.02∗∧ | 0.148 ± 0.09∗∧ | 0.346 ± 0.02#∧ | 0.264 ± 0.05#∗ | 0.38 ± 0.02#∧ | 0.302 ± 0.02# |
| Serum MDA ( | 3.27 ± 0.41∗∧ | 3.72 ± 0.31∗∧ | 11.48 ± 1.12# | 12 ± 0.59# | 6.77 ± 1.07#∗∧ | 12.54 ± 0.84# |
| Serum protein carbonyl ( | 1123.29 ± 61.71∗∧ | 1214.74 ± 59.3∗∧ | 1513.02 ± 31.18#∧ | 1393.33 ± 71.4#∗ | 1195.76 ± 38.84∗∧ | 1134.95 ± 57.94∗∧ |
| Serum TAC ( | 1.30 ± 0.03#∗∧ | 1.25 ± 0.03∗∧ | 0.86 ± 0.03# | 0.83 ± 0.02# | 0.87 ± 0.04# | 0.93 ± 0.02#∗∧ |
| Serum GSH (mmol/L) | 0.052 ± 0.002#∗∧ | 0.044 ± 0.011∗∧ | 0.013 ± 0.001#∧ | 0.022 ± 0.001#∗ | 0.036 ± 0.002#∗∧ | 0.032 ± 0.002#∗∧ |
| Serum SOD (U/mg protein) | 2.61 ± 0.22∗∧ | 2.39 ± 0.20∗∧ | 1.4 ± 0.2#∧ | 1.88 ± 0.14#∗ | 2.35 ± 0.22∗∧ | 2.25 ± 0.2∗ |
| Serum catalase (kU/L) | 16.64 ± 3.08∗∧ | 14.49 ± 1.02∗∧ | 6.41 ± 1.11# | 8.7 ± 0.83# | 11.56 ± 1#∗∧ | 9.68 ± 0.67#∗ |
BDL: bile duct ligation; SS: Securigera securidaca; VitC: vitamin C; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ALP: alkaline aminotransferase; LDH: lactate dehydrogenase; NO: nitric oxide; MDA: malondialdehyde; TAC: total antioxidant capacity; GSH: glutathione; SOD: superoxide dismutase. #Significantly different from the sham group; ∗significantly different from the BDL-control group; ^significantly different from the BDL+VitC group.
Figure 2Effects of Securigera securidaca seed extract on the gene expression of (a) TGF-β1, (b) caspase-3, (c) iNOS, and (d) α-SMA. #Significantly different from the sham group; ∗significantly different from the BDL-control group; ^significantly different from the BDL+VitC group.
Group comparisons respecting the mean scores of BDL-induced liver injury.
| Group | Parameters | |||
|---|---|---|---|---|
| Fibrosis mean ± SD | Inflammation mean ± SD | Duct hyperplasia mean ± SD | Necrosis mean ± SD | |
| Healthy | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Sham | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| BDL-control | 3 ± 0.71## | 2.6 ± 0.55## | 3 ± 0.71## | 3.4 ± 0.55## |
| BDL+VitC | 2 ± 0.71 | 3.6 ± 0.55 | 3.4 ± 0.89 | 3.2 ± 0.84 |
| BDL+SS100 | 1.4 ± 0.55∗∗ | 0.8 ± 0.45∗∗ | 1.4 ± 0.55∗ | 0.8 ± 0.45∗∗ |
| BDL+SS200 | 2.4 ± 0.55 | 2 ± 1 | 2.8 ± 0.84 | 2.2 ± 0.45∗ |
BDL: bile duct ligation; SS: Securigera securidaca; VitC: vitamin C; #significantly different from the sham group; ∗significantly different from the BDL-control group; ^significantly different from the BDL+VitC group.
Figure 3Effects of Securigera securidaca seed extract on the histopathological changes of the liver in BDL-afflicted rats. Representative photomicrographs of liver sections processed for H and E staining (10; scale bar 5 mm). (a) Sham X100; (b) BDL-control X100; (c) BDL-control X400; (d) BDL+VitCX100; (e) BDL+SS100 X100; and (f) BDL+SS200 X100. (a) Represents the normal liver histopathology. (b, c) Fibrosis (white arrow) and bile duct hyperplasia (red arrow) in addition to extensive tissue necrosis (green arrow) and inflammation (yellow arrow) are evident in rats with untreated BDL as shown in (b) and (c). In (d) and (c), bile duct hyperplasia is indicated by red arrow, and fibrosis is marked by white arrow. All these lesions markedly decreased in rats treated with 100 mg/kg SS seed extract.